Orphan drug designation granted to Paclical for ovarian cancer

Oasmia Pharmaceutical was granted orphan drug designation by the FDA for its drug candidate, Paclical (paclitaxel), for the treatment of ovarian cancer. Oasmia is conducting a Phase 3 study to compare the use of Paclical to Taxol in patients with ovarian cancer.  Paclical is a water soluble formulation of paclitaxel that does not require premedication and without severe Cremophor EL related side effects.

For more information visit www.oasmia.com.